ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy
Smith S, Su D, de la Longrais I, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D. ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy. Journal Of Clinical Oncology 2007, 25: 5172-5179. PMID: 18024864, DOI: 10.1200/jco.2007.11.8547.Peer-Reviewed Original ResearchConceptsExcision repair cross-complementation group 1High ERCC1 expressionOvarian cancer patientsERCC1 expressionC genotypeDisease progressionGreater riskCancer patientsTreatment responseCodon 118Postoperative platinum-based chemotherapyEpithelial ovarian cancer patientsLow ERCC1 expressionSurvival of patientsPlatinum-based chemotherapyEpithelial ovarian cancerERCC1 mRNA expressionCombination of platinumERCC1 genotypePlatinum chemotherapyPoor prognosisOvarian cancerPaclitaxel treatmentGroup 1T genotype